Impact of Enzalutamide, An Androgen Receptor Signaling Inhibitor, on Time to First Skeletal Related Event (SRE) and Pain in the Phase 3 Affirm Study

null null Background null Enzalutamide-proposed INN (ENZA, MDV3100) inhibits androgen binding to AR, AR nuclear translocation, and AR association with DNA. The AFFIRM trial (NCT00974311) demonstrated that ENZA increased survival by 4.8 mo (P null null null null Methods null In the double-blind, multinational Phase 3 AFFIRM study pts were randomized 2:1 to ENZA 160 mg/d or placebo. Corticosteroids were allowed but not required. Patients were...